ANTI-REUMINA

Name
ANTI-REUMINA

Active ingredients
Each tablet contains: Active ingredients: Acetylsalicylic acid 275 mg Paracetamol 175 mg Caffeine 25 mg

Therapeutic indications
Symptomatic treatment of headache, neuralgia, toothache, menstrual pain, joint pain, feverish states and cold syndromes.

Dosage
Adults: 1 to 4 tablets per day. Do not exceed the recommended doses; in particular, elderly patients should adhere to the minimum dosages indicated above. The product should be taken on a full stomach.

Conservation
Store at room temperature.

Pregnancy and breastfeeding
Pregnancy Use of the product is contraindicated during the third trimester of pregnancy. ANTIREUMINA contains acetylsalicylic acid (ASA). Clinical studies indicate that ASA doses up to 100 mg/day can be considered safe for obstetric use only, which requires specialist monitoring. - ASA doses 100-500 mg/day. There are insufficient clinical data on the use of doses above 100 mg/day up to 500 mg/day. Therefore, the recommendations below for doses of 500 mg/day and above also apply to this dosage range. - ASA doses 500 mg/day and above Inhibition of prostaglandin synthesis may adversely affect pregnancy and/or embryo/fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1%, up to approximately 1.5%. The risk was believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-foetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy, acetylsalicylic acid should not be given unless clearly necessary. If acetylsalicylic acid is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose and duration of treatment should be kept as low as possible. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which may progress to renal failure with oligo-hydroamniosis. the mother and the neonate, at the end of pregnancy, to: - possible prolongation of bleeding time, and antiaggregant effect which may occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, acetylsalicylic acid at doses > 100 mg/day is contraindicated during the third trimester of pregnancy. Paracetamol A large amount of data on pregnant women indicate neither malformative nor fetal/neonatal toxicity. Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results. If clinically necessary, paracetamol can be used during pregnancy, however it should be used at the lowest effective dose for the shortest possible time and with the lowest possible frequency.